全文获取类型
收费全文 | 1550篇 |
免费 | 185篇 |
国内免费 | 18篇 |
专业分类
耳鼻咽喉 | 22篇 |
儿科学 | 125篇 |
妇产科学 | 30篇 |
基础医学 | 144篇 |
口腔科学 | 57篇 |
临床医学 | 189篇 |
内科学 | 326篇 |
皮肤病学 | 12篇 |
神经病学 | 66篇 |
特种医学 | 211篇 |
外科学 | 290篇 |
综合类 | 43篇 |
预防医学 | 62篇 |
眼科学 | 8篇 |
药学 | 80篇 |
中国医学 | 5篇 |
肿瘤学 | 83篇 |
出版年
2021年 | 22篇 |
2020年 | 14篇 |
2019年 | 13篇 |
2018年 | 42篇 |
2017年 | 47篇 |
2016年 | 41篇 |
2015年 | 50篇 |
2014年 | 45篇 |
2013年 | 77篇 |
2012年 | 53篇 |
2011年 | 55篇 |
2010年 | 75篇 |
2009年 | 69篇 |
2008年 | 60篇 |
2007年 | 59篇 |
2006年 | 55篇 |
2005年 | 48篇 |
2004年 | 37篇 |
2003年 | 36篇 |
2002年 | 36篇 |
2001年 | 24篇 |
2000年 | 21篇 |
1999年 | 19篇 |
1998年 | 65篇 |
1997年 | 60篇 |
1996年 | 59篇 |
1995年 | 53篇 |
1994年 | 32篇 |
1993年 | 40篇 |
1992年 | 29篇 |
1991年 | 25篇 |
1990年 | 28篇 |
1989年 | 24篇 |
1988年 | 32篇 |
1987年 | 32篇 |
1986年 | 20篇 |
1985年 | 19篇 |
1984年 | 15篇 |
1983年 | 20篇 |
1982年 | 9篇 |
1981年 | 21篇 |
1980年 | 11篇 |
1979年 | 10篇 |
1978年 | 16篇 |
1977年 | 19篇 |
1976年 | 18篇 |
1975年 | 7篇 |
1973年 | 8篇 |
1971年 | 17篇 |
1970年 | 14篇 |
排序方式: 共有1753条查询结果,搜索用时 15 毫秒
1.
2.
S. Vitko Z. Wlodarczyk L. Kyllönen Z. Czajkowski R. Margreiter L. Backman F. Perner P. Rigotti B. Jaques D. Abramowicz M. Kessler J. Sanchez-Plumed L. Rostaing R.S. Rodger D. Donati Y. Vanrenterghem 《American journal of transplantation》2006,6(3):531-538
Tacrolimus combined with mycophenolate mofetil (MMF) is an effective regimen in kidney transplantation. This study compared the efficacy of combining tacrolimus and two different dosages of sirolimus with an established tacrolimus-MMF regimen. Each day in addition to tacrolimus, 325 patients received 2 mg sirolimus (TAC-SRL2 mg), 325 patients received 0.5 mg sirolimus (TAC-SRL0.5 mg) and 327 patients 1 g MMF (TAC-MMF). The initial tacrolimus dose was 0.2 mg/kg/day. Sirolimus patients received loading doses of 6 or 1.5 mg, and daily doses of 2 or 0.5 mg thereafter. Steroid administration was identical for all groups. The incidence of biopsy-proven acute rejection was lower in the TAC-SRL2 mg group (15.7%) compared with the TAC-SRL0.5 mg (25.2%, p = 0.003) and the TAC-MMF groups (22.3%, p = 0.036). Six-month graft survival was 91.0% (TAC-SRL2 mg), 92.6% (TAC-SRL0.5 mg) and 92.4% (TAC-MMF); the respective values for patient survival were 98.1%, 97.8% and 97.9%. Thirty-four patients (10.5%), 19 patients (5.8%) and 16 patients (4.9%) in the TAC-SRL2 mg, TAC-SRL0.5 mg and TAC-MMF groups, respectively, discontinued the study because of adverse events. Hyperlipemia was reported more often in the TAC-SRL2 mg group (24.0%) compared with 19.4% (TAC-SRL0.5 mg) and 11.0% (TAC-MMF; p < 0.05). Combining 2 mg sirolimus/day with tacrolimus results in lower rates of acute rejection, but a higher incidence of adverse events. 相似文献
3.
M. S. Reddy S. A. White B. C. Jaques N. Torpey D. M. Manas 《American journal of transplantation》2007,7(10):2422-2424
As demand for donor pancreases increases, attempts are being made to utilize even marginal grafts for transplantation. Injury during pancreas recovery can predispose to posttransplant complications and graft loss. Early recognition and correction can salvage these grafts. The authors report an instance of poor segmental perfusion of the pancreas graft that was salvaged by pancreas head resection and enteric drainage through a Roux-en-Y pancreatico-jejunostomy. 相似文献
4.
Benign intracranial hypertension and recombinant growth hormone therapy in Australia and New Zealand
PA Crock JD McKenzie AM Nicoll NJ Howard W Cutfield LK Shield G Byrne 《Acta paediatrica (Oslo, Norway : 1992)》1998,87(4):381-386
Benign intracranial hypertension (BIH) is reported in three children from Australia and one from New Zealand, who were being treated with recombinant human growth hormone (rhGH). Three males and one female, aged between 10.5 and 14.2 y, developed intracranial hypertension within 2 weeks to 3 months of starting treatment. A national database, OZGROW, has been prospectively collecting data on all 3332 children treated with rhGH in Australia and New Zealand from January 1986 to 1996. The incidence of BIH in children treated with growth hormone (GH) is small, 1.2 per 1000 cases overall, but appears to be greater with biochemical GHD (<10IUml -1 ), i.e. 6.5/1000 (3 in 465 cases), relative risk 18.4, 95% confidence interval 1.9-176.1, than in all other children on the database. The incidence in patients with Turner's syndrome was 2.3/1000 (1 in 428 cases). No cases in patients with partial GHD (10–20 IUml -1 ) or chronic renal failure were identified. Possible causative mechanisms are discussed. The authors'practice is now to start GH replacement at less than the usual recommended dose of 14IUm-2 week-1 in those children considered to be at high risk of developing BIH. Ophthalmological evaluation is recommended for children before and during the first few months following commencement of rhGH therapy and is mandatory in the event of peripheral or facial oedema, persistent headaches, vomiting or visual symptoms. The absence of papilledema does not exclude the diagnosis. 相似文献
5.
In a prospective, randomized, double-blind study, 49 patients underwent lumbar myelography using iotrol (24 patients) or metrizamide (25 patients). The diagnostic imaging adequacy of iotrol was comparable with that of metrizamide. After iotrol myelography, adverse reactions were fewer, less severe, and of shorter duration than were those following metrizamide myelography. Thirteen of 24 patients (54%) receiving iotrol reported some adverse reactions compared with 24 of 25 patients (96%) receiving metrizamide. Five moderate and one severe adverse reaction occurred in the group receiving iotrol. Fourteen moderate and eight severe adverse reactions occurred in the group receiving metrizamide. Thirty-eight patients underwent electroencephalography both before and after myelography (19 iotrol and 19 metrizamide). None of the EEGs obtained after iotrol myelography changed from baseline, while seven of the EEGs obtained after metrizamide myelography showed changes from baseline. Iotrol was judged superior to metrizamide as a contrast medium in this patient population. 相似文献
6.
7.
8.
9.
Paul F. Jaques Matthew A. Mauro Jeet Sandhu 《Cardiovascular and interventional radiology》1997,20(3):211-212
The hepatic falciform artery is an occasional terminal branch of the left or middle hepatic artery, and may provide an uncommon
but important collateral route when the principal visceral arteries are occluded. 相似文献
10.